Artiva Biotherapeutics, Inc. filed a Form 8-K on September 11, 2026, reporting the voting results from its 2026 Annual Meeting of Stockholders held on September 8, 2026, including stockholder approval of an amendment to its 2024 Equity Incentive Plan.

Key Highlights

  • Equity plan expanded: Stockholders approved an increase of 5,097,095 shares of common stock authorized for issuance under the Amended 2024 Equity Incentive Plan.
  • Pre-funded warrants included: The amendment adds shares issuable upon exercise of pre-funded warrants to the annual automatic share reserve increase calculation.
  • Two Class II directors elected: Brian Daniels, M.D. and Laura Stoppel, Ph.D. were each elected to serve three-year terms through the 2029 annual meeting.
  • KPMG LLP ratified: Stockholders ratified KPMG LLP as principal independent registered public accounting firm for the fiscal year ending December 31, 2026, with 44,000,762 votes in favor.
  • Record date shares: As of July 20, 2026, 48,885,777 shares of common stock were outstanding and entitled to vote.
  • Board pre-approval: The amended plan was approved by the Board of Directors on July 15, 2026, subject to stockholder approval.

Artiva Biotherapeutics Stockholders Approve Equity Plan Amendment and Elect Directors at 2026 Annual Meeting

According to the filing, Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) held its 2026 Annual Meeting of Stockholders on September 8, 2026, at which three proposals were submitted to a vote. The record date for the meeting was July 20, 2026, when 48,885,777 shares of common stock were outstanding and entitled to vote.

On Proposal 1, stockholders elected Brian Daniels, M.D. and Laura Stoppel, Ph.D. as Class II directors, each to serve a three-year term through the Company's 2029 annual meeting. The filing reports that Daniels received 33,591,967 votes for and 5,774,914 votes withheld, while Stoppel received 33,862,513 votes for and 5,504,368 votes withheld. Both nominees carried 4,640,922 broker non-votes. On Proposal 2, stockholders ratified the appointment of KPMG LLP as principal independent registered public accounting firm for fiscal year ending December 31, 2026, with 44,000,762 votes for, 4,325 votes against, and 2,716 abstentions.

Proposal 3 sought stockholder approval of an amendment to the Company's 2024 Equity Incentive Plan. According to the filing, the amendment increases the number of shares of common stock authorized for issuance under the plan by 5,097,095 shares and adds shares issuable upon exercise of any pre-funded warrants to the annual automatic share reserve increase calculation. The proposal passed with 32,527,133 votes for, 6,816,989 votes against, 22,759 abstentions, and 4,640,922 broker non-votes. The filing notes that the Board had approved the amendment on July 15, 2026, subject to stockholder approval, and that the Amended 2024 Plan is filed as Exhibit 10.1 to the report.

What Was Disclosed

Artiva Biotherapeutics disclosed 2026 Annual Meeting voting outcomes covering director elections, auditor ratification, and an equity incentive plan amendment that adds 5,097,095 authorized shares and incorporates pre-funded warrants into the automatic share reserve increase formula.